NIKI (Niki BioSolutions) Beginning Cash Position: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKI Niki BioSolutions Inc NIKI
34 GF Score
Price $6.23
! 1 Warning Sign
View Full Analysis

What is Niki BioSolutions Beginning Cash Position?

Niki BioSolutions NIKI -4.76% 34 Beginning Cash Position is $0.00 Mil as of Dec. 2025. GuruFocus rates NIKI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Niki BioSolutions's Beginning Cash Position for the quarter that ended in Dec. 2025 was $0.00 Mil.

Niki BioSolutions's annual Beginning Cash Position declined from Dec. 2023 ($5.01 Mil) to Dec. 2024 ($2.01 Mil) and declined from Dec. 2024 ($2.01 Mil) to Dec. 2025 ($0.88 Mil).

Niki BioSolutions Beginning Cash Position Related Terms

Niki BioSolutions Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Niki BioSolutions's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niki BioSolutions Beginning Cash Position Chart

Niki BioSolutions Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 3.63 8.26 5.01 2.01 0.88

Niki BioSolutions Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NIKI
34GF Score
Niki BioSolutions Inc NIKI
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niki BioSolutions Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.00 Mil mean?
Niki BioSolutions (NIKI) has a Beginning Cash Position of $0.00 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Niki BioSolutions and its competitors.
Is Niki BioSolutions' Beginning Cash Position too high?
Niki BioSolutions' current Beginning Cash Position is $0.00 Mil. Overall, Niki BioSolutions has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' Beginning Cash Position compare to KAPA and LIMN?
Niki BioSolutions' Beginning Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Niki BioSolutions and its competitors. Niki BioSolutions's current Beginning Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Niki BioSolutions (NIKI) has a current Beginning Cash Position of $0.00 Mil. The current Beginning Cash Position is $0.00 Mil. Niki BioSolutions' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current Beginning Cash Position is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Niki BioSolutions Business Description

Address 17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
34GF Score

Get the complete analysis for NIKI

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.23
Price